Zydus Lifesciences · tone and specificity signals across the available quarters.
Language signals
We are willing for a next FY28 launch. The first two years will be just a buildup of this. So we won't see any significant revenue in the first year, but as we move into second and third year we would see the revenue build up.
On our conservative side we're looking at a 200 to 300 million range and we may be more optimistic we can cross the 400 plus million range.
If we are able to scale up a branded business towards the 2/3 then we should see an improvement in our margins. Ideally we would want to be improving our EBITDA margins to the 28-30% range as we move closer to the 5-year period long.
We will see a meaningful cost on Saro in FY27 and we are not quantifying. I think it's too early to give a guidance but it'll be meaningful and it'll be building up as we move through the year.
We are quite bullish on double-digit growth for India. We have a strong momentum for our innovative brands. Also, we will have Saro launch as well as many other interesting first day one launches in the market.
It is mostly contingent on if we get to see any major opportunity. Our internal approvals are in place and cash flows are sufficient for us to continue to do what we need to do without fundraise. Fund raise is an enabling provision for us to use if we feel we need to provided we can see any meaningful acquisition.